Invitrogen’s drug discovery products will be validated on selected Tecan microplate readers and instruments, starting with the Infinite series readers. Initial certifications will focus on Invitrogen’s assay systems for key target classes, such as LanthaScreen Tr-Fret for protein kinases, GeneBLAzer reporter-gene technology for G protein-coupled receptors. This collaboration will allow Tecan and Invitrogen to develop and promote joint applications for the drug discovery market.
John Printen, director of cell signaling at Invitrogen, said: “Through this partnership with Tecan, we will be able to provide integrated instrumentation and reagent solutions to the research community.”